TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12051959
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) at a dose of 4 g/day
Study: 10192648
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels at or above the 97.5th centile (6.17 mg/L)
Study: 7730940
Drug: Nurse-coordinated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-coordinated intervention (telephone contacts at least monthly)
Study: 2292537
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous ciprofloxacin
Study: 29152243
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 8 weeks
Study: 28800861
Drug: Ipatasertib 400
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 400 mg once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15)
Study: 28800861
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15)
Study: 28800861
Drug: Ipatasertib 400
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 400 mg once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15) in PTEN-low population
Study: 28800861
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once per day (days 1-21) plus intravenous paclitaxel 80 mg/m2 (days 1, 8, 15) in PTEN-low population
Study: 25457470
Drug: TXA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (100 mg/Kg loading dose over 20 minutes, followed by 10 mg/Kg/h until skin closure)
Study: 25457470
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline infusion of similar volume)
Study: 27841849
Drug: Topical apraclonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical apraclonidine 0.5%
Study: 22118999
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide
Study: 17095879
Drug: No hypotensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hypotensive treatment (control group)
Study: 7801083
Drug: Shortened i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened i.v. treatment duration (1-3 days)
Study: 3137626
Drug: Pipequaline 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipequaline 50 mg
Study: 3137626
Drug: Pipequaline 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipequaline 150 mg
Study: 3137626
Drug: Pipequaline 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipequaline 50 mg + Diazepam 10 mg
Study: 3137626
Drug: Pipequaline 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipequaline 150 mg + Diazepam 10 mg
Study: 26990963
Drug: Glucocorticoid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid group (inhaled with Seretide/Pulmicort)
Study: 21636122
Drug: Dexamethasone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (5 mg once a day for 4 days)
Study: 21287803
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Cosopt)
Study: 21287803
Drug: Carbonic anhydrase
Normalized name: Carbonic anhydrase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbonic anhydrase inhibitors (CAI)
Study: 16566363
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive system (TCS) with 20 microg ethinyl estradiol (EE) and 150 microg norelgestromin (17‐dNGM)
Study: 16566363
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 20 microg EE and 150 microg desogestrel
Study: 11069322
Drug: Tegaserod 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 1 mg/day
Study: 11069322
Drug: Tegaserod 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 4 mg/day
Study: 11069322
Drug: Tegaserod 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 1 mg/day and 4 mg/day
Study: 8117608
Drug: P-100 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-100 administered for ten days following chemotherapy during the first cycle
Study: 8117608
Drug: P-100 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-100 administered for ten days following chemotherapy during the second cycle
Study: 28695570
Drug: Monthly mass
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly mass drug administration of dihydroartemisinin-piperaquine
Study: 28695570
Drug: Bimonthly mass
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimonthly mass drug administration of dihydroartemisinin-piperaquine
Study: 28695570
Drug: Single low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single low dose of primaquine added to DHA-piperaquine treatment
Study: 25255776
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine treatment
Study: 24708031
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg once daily)
Study: 22727160
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 μg twice daily)
Study: 10730908
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day for 12 weeks (T12)
Study: 10730908
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day for 16 weeks (T16)
Study: 10730908
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg/day for 1 week in every 4 weeks for 12 weeks (I3)
Study: 10730908
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg/day for 1 week in every 4 weeks for 16 weeks (I4)
Study: 12959310
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ramipril 2.5 mg and felodipine ER 5 mg
Study: 3303792
Drug: Methimazole 10
Normalized name: methimazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 10 mg
Study: 3303792
Drug: Methimazole 40
Normalized name: methimazole 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 40 mg
Study: 2524203
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone supplementation
Study: 28088207
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection (specifics not provided)
Study: 26602093
Drug: Telephone Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone Cognitive Behavioral Therapy (tCBT) with motivational interviewing techniques
Study: 24051942
Drug: Metformin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (3 g)
Study: 24051942
Drug: Metformin (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.7 g), myo-inositol, and alpha-lipoic acid
Study: 12659599
Drug: Atorvastatin 10-20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10-20 mg/d
Study: 12659599
Drug: Simvastatin 10-20
Normalized name: ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Simvastatin 10-20 mg/d
Study: 1705386
Drug: Sotalol 640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 640 mg/day
Study: 2428852
Drug: Sotalol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (both doses)
Study: 30567497
Drug: Checklist intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Checklist intervention for antihypertensive medication initiation
Study: 17412473
Drug: Flupentixol (4-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol (4-12 mg/d)
Study: 17412473
Drug: Risperidone (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2-6 mg/d)
Study: 10503165
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg once daily)
Study: 10503165
Drug: Terazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (2 mg once daily)
Study: 2683541
Drug: Intrapleural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural bupivacaine (bolus 20 ml followed by 10 ml/h)
Study: 2683541
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (bolus 9 ml followed by 5 ml/h)
Study: 26663024
Drug: Cortisol geometric
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol geometric means (nmol/l) for women with ≤5.5 hot flashes per day, N = 103
Study: 26663024
Drug: Cortisol geometric
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol geometric means (nmol/l) for women with >5.5-8.8 hot flashes per day, N = 103
Study: 26663024
Drug: Cortisol geometric
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol geometric means (nmol/l) for women with >8.8 hot flashes per day, N = 100
Study: 26663024
Drug: Cortisol geometric
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol geometric means (nmol/l) for all women
Study: 25037988
Drug: Interruption group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption group (single aspirin treatment after thienopyridine interruption)
Study: 22952176
Drug: Meat (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat (30 to 45 g daily)
Study: 18936474
Drug: Vandetanib monotherapy
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib monotherapy
Study: 18058066
Drug: Sustained inflation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained inflation of the intrarectal balloon with 30 and 60 mL air
Study: 18058066
Drug: Rapid inflation/deflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid inflation/deflation of the intrarectal balloon with 30 and 60 mL air
Study: 1855083
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Vincristine (4 mg/m2), TBI (1200 cGy), Cyclophosphamide (3600 mg/m2) as standard conditioning regimen before transplant
Study: 6340878
Drug: sulphinpyrazone, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphinpyrazone, 4 x 200 mg daily for 7 days
Study: 28342739
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy (PT)
Study: 25741817
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (500 mg OD aspirin for 7 days)
Study: 26700124
Drug: Low Molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Molecular Weight Heparin (LMWH) for 24 weeks
Study: 17329466
Drug: Quetiapine (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (200-800 mg/day)
Study: 16889453
Drug: Risperidone (2-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2-8 mg/day)
Study: 14998418
Drug: Optimization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of drug prescribing
Study: 11028832
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tropisetron
Study: 15100522
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate tablets
Study: 19491652
Drug: Stavudine 30
Normalized name: stavudine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 30 mg
Study: 7780046
Drug: Stavudine 40
Normalized name: stavudine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 40 mg
Study: 16911100
Drug: Rofecoxib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib + Paracetamol
Study: 11209089
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) plus G-CSF (arm A)
Study: 11209089
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) plus GM-CSF followed by G-CSF (arm C)
Study: 9232040
Drug: Auralgan otic
Normalized name: Auralgan Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auralgan otic solution (combination product of antipyrine, benzocaine, and glycerin)
Study: 8356980
Drug: Low-dose trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose trimethoprim-sulfamethoxazole (TMP 40 mg, SMX 200 mg) once daily
Study: 332262
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg hemisuccinate hydrocortisone (HSHC)
Study: 332262
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg hemisuccinate hydrocortisone (HSHC)
Study: 332262
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg hemisuccinate hydrocortisone (HSHC)
Study: 27778328
Drug: Isotretinoin 10
Normalized name: isotretinoin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 10 mg every other day
Study: 27778328
Drug: Antiseborrheic topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseborrheic topical treatment
Study: 15477550
Drug: l-methionine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-methionine 6 g/day in two divided doses
Study: 29929813
Drug: IncobotulinumtoxinA (IncoA)
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: IncobotulinumtoxinA (IncoA) injection, 80–120 units, customized injection approach
Study: 14722514
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg/d)
Study: 10099857
Drug: Flunarizine 10
Normalized name: flunarizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 10 mg at bedtime for 1 and 3 months
Study: 10099857
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BRC) 2.5 mg
Study: 1651201
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg.day‐1)
Study: 29870446
Drug: Corticosteroid +
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid + lidocaine (40 mg triamcinolone acetonide plus 5 mL of 1% lidocaine)
Study: 29870446
Drug: Lidocaine alone
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine alone (6 mL of 1% lidocaine)
Study: 25323182
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + clavulanic acid (Group A)
Study: 25323182
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (Group C)
Study: 19777494
Drug: Treatment under
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment under per-protocol analysis
Study: 19777494
Drug: Noncompliance by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncompliance by switching treatment
Study: 19777494
Drug: Noncompliance by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncompliance by subjects not receiving any treatment
Study: 17335319
Drug: Perphenazine (8-64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (8-64 mg/day)
Study: 15215002
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for 2 hours
Study: 31923800
Drug: Matched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched treatment
Study: 9642894
Drug: Mismatched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mismatched treatment
Study: 31218531
Drug: Medication +
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication + CT
Study: 31218531
Drug: Medication +
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication + non-active training
Study: 31003673
Drug: Scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp acupuncture combined with exercise therapy and conventional rehabilitation training
Study: 23989947
Drug: Plitidepsin 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 2.4 mg m(‐2) combined with DTIC 800 mg m(‐2) q4wk (n = 38)
Study: 23989947
Drug: Single-agent plitidepsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent plitidepsin 3.2 mg m(‐2) (n = 20)
Study: 18466359
Drug: Asimadoline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asimadoline 0.5 mg
Study: 18331462
Drug: Asimadoline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asimadoline 1.0 mg
Study: 15656399
Drug: Dipyridamole (curantyl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (curantyl, 100 mg a week)
Study: 11895512
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol
Study: 9703125
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin
Study: 8198936
Drug: Imidapril 5
Normalized name: imidapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 5 mg
Study: 8198936
Drug: Imidapril 20
Normalized name: imidapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 20 mg
Study: 8181800
Drug: Imidapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (5 mg and 20 mg)
Study: 3371098
Drug: Single sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single sclerotherapy treatment with tetracycline at a dose of 20 mg/kg
Study: 3371098
Drug: Two sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sclerotherapy treatments with tetracycline
Study: 30343531
Drug: IXEQ2W (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXEQ2W (80 mg subcutaneous ixekizumab every 2 weeks)
Study: 30343531
Drug: IXEQ4W (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXEQ4W (80 mg subcutaneous ixekizumab every 4 weeks)
Study: 29095374
Drug: Dialectical Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavioral Therapy-Case Management (DBT-CM)
Study: 22026392
Drug: Oral atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atorvastatin 40 mg/day
Study: 10952952
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (rich in fruits, vegetables, and low-fat dairy products, reduced in saturated and total fat)
Study: 8620234
Drug: Cromolyn sodium,
Normalized name: Cromolyn Sodium, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn sodium, 20 mg four times a day for 8 weeks and 20 mg three times a day for 8 weeks
Study: 8620234
Drug: Budesonide, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 500 micrograms twice a day for 8 weeks and 250 micrograms twice a day for 8 weeks
Study: 1468164
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg three times a day for three days)
Study: 23294774
Drug: Adaptive, dose-finding,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive, dose-finding, seamless phase 2/3 trial
Study: 23294774
Drug: Drug supply
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug supply management for nine treatment arms
Study: 9890620
Drug: Malignant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malignant group (treated with antineoplastic agents)
Study: 7745044
Drug: Timed intercourse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed intercourse with cyclic, low-dose prednisolone (20 mg)
Study: 6775301
Drug: Sustained-release nitroglycerin
Normalized name: nitroglycerin Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nitroglycerin capsules
Study: 17786056
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II Receptor Blockers (ARBs)
Study: 17786056
Drug: Angiotensin-Converting Enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-Converting Enzyme (ACE) inhibitors
Study: 28509727
Drug: Calcium Channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Channel Blockers (CCBs)
Study: 28894283
Drug: JinqiJiangtang tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: JinqiJiangtang tablets (JQJT tablets)
Study: 25643028
Drug: Alcohol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (target BrAC = .08 g%) in lab context
Study: 25643028
Drug: Alcohol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (target BrAC = .08 g%) in simulated bar context
Study: 21115863
Drug: IV amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV amifostine (200 mg/m(2) daily for 3 minutes, 15 to 30 minutes before irradiation)
Study: 21115863
Drug: SC amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC amifostine (500 mg; two sites; 20 to 60 minutes before irradiation)
Study: 19263186
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of oral L‐amphetamine sulfate for 29 days
Study: 23098346
Drug: Losartan 12.5
Normalized name: losartan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 12.5 mg
Study: 10225572
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet
Study: 8904626
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg tablet
Study: 8904626
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg solution
Study: 8904626
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg tablet with food
Study: 8904626
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg tablet fasting